Demographics | Death (%) Patients, n = 6 | No Death (%) Patients, n = 31 | p |
---|---|---|---|
Sex | 3 male | 4 male | 0.014 |
Age | 62 ± 12 | 58.5 ± 13 | 0.52 |
Race | 4 AA, 2 W | 10 AA, 21 W | 0.169 |
Disease characteristics | Cases, n = 6 | Cases, n = 58 (%) | |
Raynaud phenomenon | 3 | 37 (64) | 0.663 |
Digital ulcers | 2 | 13 (22) | 0.621 |
Interstitial lung disease | 2 | 15 (26) | 0.652 |
Pulmonary arterial hypertension | 2 | 24 (41) | 1 |
Esophageal involvement | 0 | 42 (72) | 0.001 |
Gastric involvement | 0 | 17 (29) | 0.181 |
Bacterial overgrowth | 0 | 9 (16) | 0.581 |
Opioids (on admission) | 2 | 9 (16) | 0.278 |
Promotility (on admission) | 4 | 29 (50) | 0.673 |
Symptoms | |||
Diarrhea | 0 | 9 (16) | 0.579 |
Abdominal pain | 0 | 28 (48) | 0.031 |
Nausea | 3 | 45 (77) | 0.159 |
Weight loss | 1 | 9 (16) | 1 |
Hematochezia | 0 | 1 (2) | 1 |
Melena | 0 | 2 (3) | 1 |
Fever | 0 | 4 (7) | 1 |
Laboratory values | |||
Hemoglobin | 9.9 ± 0.6 | 12 ± 2.1 | 0.00008 |
White blood cell count | 11.2 ± 4.4 | 10.7 ± 5.8 | 0.831 |
AST | 42 ± 48 | 36 ± 26 | 0.799 |
ALT | 18 ± 6.4 | 33 ± 35 | 0.018 |
Total bilirubin | 0.6 ± 0.05 | 0.78 ± 1.1 | 0.454 |
ALP | 68 ± 33 | 124 ± 75 | 0.013 |
Creatinine | 1.8 ± 1.8 | 1 ± 0.5 | 0.405 |
Albumin | 2.5 ± 0.5 | 3.7 ± 0.9 | 0.001 |
Lipase | 17 ± 8.5 | 86 ± 199 | 0.058 |
Amylase | 71 ± 21 | 110 ± 66 | 0.03 |
Treatment modality | |||
NPO | 4 | 42 (72) | 0.629 |
Surgery | 2 | 3 (5) | 0.065 |
Nasogastric tube | 6 | 20 (34) | 0.003 |
Prokinetic | 4 | 27 (47) | 0.419 |
Antibiotics | 1 | 19 (33) | 0.653 |
Intravenous fluids | 3 | 38 (66) | 0.658 |
Total parenteral nutrition | 1 | 21 (36) | 0.655 |
Outcome | |||
Spontaneous resolution | 0 | 45 (76) | 0.0004 |
Prolonged TPN | 0 | 16 (27) | 0.0001 |
Days hospitalized | 27 ± 21 | 10.1 ± 9.9 | 0.098 |
SSc: systemic sclerosis; AA: African American; W: white; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; NPO: nil per os; TPN: total parenteral nutrition.